Literature DB >> 19193110

Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients.

Hsin-Yun Sun1, Nina Singh.   

Abstract

Statins are increasingly being used to treat solid-organ transplant recipients for posttransplantation metabolic complications. In addition to improving dyslipidemia, statins also have manifold non-lipid-lowering effects. With regard to sepsis or infection, these agents modify the inflammatory cascades by pleiotropic actions at multiple levels and exhibit activities against opportunistic bacteria, fungi, and viruses that can cause serious infections in solid-organ transplant recipients. They also have synergistic interactions with antimicrobial agents. Statins with antimicrobial and immunomodulatory attributes might improve morbidity and mortality attributable to sepsis or infection in solid-organ transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193110     DOI: 10.1086/597039

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.

Authors:  Eric M Mortensen; Brandy Nakashima; John Cornell; Laurel A Copeland; Mary Jo Pugh; Antonio Anzueto; Chester Good; Marcos I Restrepo; John R Downs; Christopher R Frei; Michael J Fine
Journal:  Clin Infect Dis       Date:  2012-08-23       Impact factor: 9.079

2.  Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.

Authors:  Elias K Spanakis; Themistoklis K Kourkoumpetis; Grigorios Livanis; Anton Y Peleg; Eleftherios Mylonakis
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

3.  Effect of statins on outcomes in immunosuppressed patients with bloodstream infection.

Authors:  D Viasus; C Gudiol; N Fernández-Sabé; I Cabello; C Garcia-Vidal; M Cisnal; R Duarte; M Antonio; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-12       Impact factor: 3.267

4.  Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Authors:  Tracey G Simon; Hector Bonilla; Peng Yan; Raymond T Chung; Adeel A Butt
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

5.  Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.

Authors:  Tracey G Simon; Lindsay Y King; Hui Zheng; Raymond T Chung
Journal:  J Hepatol       Date:  2014-08-15       Impact factor: 25.083

Review 6.  Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Sehrish Kamal; Muhammad Ali Khan; Ankur Seth; George Cholankeril; Deepansh Gupta; Utkarsh Singh; Faisal Kamal; Colin W Howden; Christopher Stave; Satheesh Nair; Sanjaya K Satapathy; Aijaz Ahmed
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

7.  High serum cholesterol levels are associated with herpes zoster infection after heart transplantation.

Authors:  Jose L Del Pozo; Diederik van de Beek; Jayawant N Mandrekar; Richard C Daly; Christopher G A McGregor; Jose R Azanza; Robin Patel
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

Review 8.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 9.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

10.  Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.

Authors:  Majed Masadeh; Nizar Mhaidat; Karem Alzoubi; Sayer Al-Azzam; Ziad Alnasser
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-05-07       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.